PGY2 Resident Pharmacist Advocate Health Milwaukee, Wisconsin, United States
Poster Abstract:
Background:
Advocate Health is a multihospital, multistate, integrated health system with 27 hospitals expanding across Wisconsin and Illinois. Advocate Health has an inpatient formulary of over 2500 medications to guide appropriate medication selection. To better manage our healthcare dollars, many oncology medications are restricted to outpatient use due to cost, safety, or other use criteria. Despite the restrictions to outpatient, some hospitalized patients receive these restricted medications inpatient. Inappropriate use of restricted medications can result in considerable cost to the organization and/or the patient.
Objectives:
The purpose of this project is to quantify outpatient restricted medications being given in the inpatient setting. The aim is to identify the frequently administered restricted medications and further assess the discharge disposition of these patients. Within 2 weeks of receiving the restricted medication, patients were evaluated for time to discharge, time to hospice, and/or time to expiration. This information will be presented to the healthcare team for review of use and future prescribing guidance.
Methods:
Methodology of this project started with a literature search to determine if other institutions have a process in place that could be utilized as a model at Advocate Health. There was a wealth of resources available, in both the oncology and non-oncology setting, regarding the cost-saving benefits of formulary restrictions. There was, however, limited data available for clinical outcomes associated with formulary restricted medications.
SlicerDicer, a data reporting program, was utilized to collect information on restricted medication administration in the hospital and discharge disposition status of these patients. Several limitations of the report were identified and addressed. Other reports were utilized and compared to the SlicerDicer data. Manual data collection was also performed to supplement the report and ensure validity of the data.
After further analysis of this information, it will be presented to our system-based Cancer Quality Subcommittee for further action.
Results:
Pending.
Discussion/
Conclusion:
Pending.
References (must also be included in final poster): No references for current material.
